Addition Therapeutics
Grady Snyder has a strong background in program and alliance management, corporate development, market planning, and operations. With experience at various pharmaceutical companies like Addition Therapeutics, Ambys Medicines, Audentes Therapeutics, BioMarin Pharmaceutical Inc., and Genzyme, Grady has expertise in portfolio strategy, R&D strategy, product planning, and product analysis. Grady holds a BS in Materials Science and Engineering from Massachusetts Institute of Technology and an MBA in Business from The Tuck School of Business at Dartmouth.
This person is not in any teams
Addition Therapeutics
Addition is transforming genetic medicine by developing RNA-only therapeutics that PRINT any genetic element at specific safe harbor sites